Treatment of symptomatic uterine leiomyomas with selective progesterone receptor modulators

Stovall, Dale W.; Mikdachi, Hana E.

doi:10.1586/eog.11.60

Search citation statements

Order By: Relevance

Paper Sections

Select...

Progesterone Receptor Agonists and Modulators1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2014

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials involving asoprisnil have reported reversible suppression of menstruation and variable effects on ovulation (Phase I);[29] reduced fibroid size in a dose-dependent manner (5, 10 and 25 mg), and a similar effect on improvement with menorrhagia with a 28–83% amenorrhea rate (Phase II);[29]improved dysfunctional bleeding and reduce fibroid size (Phase III). [19] These results are again promising, however, SPRMs like asoprisnil have not yet received FDA approval due to concerns over the effect of these agents on the endometrium.…”

Section: Progesterone Receptor Agonists and Modulatorsmentioning

confidence: 99%

Treatment for uterine fibroids: Searching for effective drug therapies

Taylor

Leppert

2012

Drug Discovery Today: Therapeutic Strategies

View full text Add to dashboard Cite

Uterine fibroids are common reproductive-age benign tumors that contribute to severe morbidity and infertility. Cumulative incidence is 4 times higher in Africian-Americans compared to Caucasians and constitutes a major health disparity challenge. Fibroids are the leading indication for hysterectomy and their management averages $21 billion annually in the US. No long term minimally invasive therapies exist. Thus, promising drug therapies, their chemistry, pharmacology, and clinical efficacy, focusing first on innovative drug delivery approaches, are reviewed.

show abstract

Section: Progesterone Receptor Agonists and Modulatorsmentioning

confidence: 99%